Shares of Intercept Pharmaceuticals Inc ICPT climbed more than 6 percent after SEC granted the company’s application requesting confidential treatment for an information it excluded from an Exhibit to a Form 10-Q filed on November 9, 2016.
As such, the excluded information will not be released to the public until December 31, 2020.
Takeover Interest?
Meanwhile, there is speculation that Intercept may be receiving a takeover bid from Novartis AG (ADR) NVS. However, the company declined to comment on the matter.
"It is our company policy not to comment on M&A speculation," a company spokesman told Benzinga.
At last check, shares of Intercept Pharma rose 6.84 percent to $111.00.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.